Home > News > Starpharma Phase 1 Preliminary Report
November 18th, 2004
Starpharma Phase 1 Preliminary Report
Abstract:
Starpharma Holdings Limited today announced that VivaGel™, its vaginal microbicidal gel for the prevention of HIV was found to be well tolerated during a clinical trial held in Australia.
VivaGel™ is the first drug product in the world based upon nanoscale dendrimers to enter human trials.
Source:
pharmalive
Related News Press |
Possible Futures
Closing the gaps — MXene-coating filters can enhance performance and reusability February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
Nanomedicine
Multiphoton polymerization: A promising technology for precision medicine February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
SMART researchers pioneer first-of-its-kind nanosensor for real-time iron detection in plants February 28th, 2025
Announcements
Closing the gaps — MXene-coating filters can enhance performance and reusability February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |